Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Cancer cell metabolism presents a promising therapeutic target.
• Developing drugs that link metabolic targeting with cancer cell death induction remains a challenge.

Purpose of the Study:

• To investigate the novel small-molecule ironomycin as a potential cancer therapeutic.
• To elucidate the mechanism of action of ironomycin in cancer cells.
• To evaluate the synergistic potential of ironomycin with existing cancer therapies.

Main Methods:

• Treatment of cancer cells with ironomycin.
• Analysis of mitochondrial metabolism and iron levels.
• Assessment of mitochondrial outer membrane permeabilization (MOMP) and cell death pathways.
• In vitro and in vivo synergy studies with venetoclax.
• Evaluation in primary patient samples, including those resistant to venetoclax.

Main Results:

• Ironomycin effectively reduces mitochondrial iron load, disrupting mitochondrial metabolism.
• Ironomycin induces BAX/BAK activation and MOMP through a novel pathway, independent of traditional programmed cell death mechanisms.
• Ironomycin demonstrates significant in vitro and in vivo synergy with venetoclax.
• Ironomycin overcomes venetoclax resistance in primary patient samples, including acute myeloid leukemia.

Conclusions:

• Ironomycin represents a novel therapeutic strategy by targeting cancer cell metabolism and inducing cell death.
• The unique mechanism of ironomycin allows for synergistic combinations with BH3 mimetics like venetoclax.
• Ironomycin holds promise for overcoming drug resistance and improving treatment outcomes in various cancers.